Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2015

View Archived Issues

Servier discloses novel Bcl-2 antagonists

Teijin Pharma reports development of novel xanthine oxidase inhibitors

Janssen discloses FLAP inhibitors

Bayer discloses BRD4 inhibitors

Takeda presents OX1 receptor antagonists

Bristol-Myers Squibb patents HIV integrase inhibitors

Lundbeck divulges BACE1 inhibitors

Neurons in Alzheimer's brains respond to nerve growth factor

Incyte discloses LSD1 inhibitors

Bayer expands finerenone program with three phase III studies

Ono Pharmaceuticals presents novel autotaxin inhibitors

Bionomics to begin phase I trial of BNC-101

Seikagaku terminates license agreement with Can-Fite BioPharma for RA product

Hisamitsu Pharmaceutical begins phase II study of HP-3150 in Japan

Eisai and Purdue to codevelop insomnia candidate lemborexant

ALK's house dust mite allergy immunotherapy approved in 11 European countries

Kanuma becomes first approved treatment in E.U. for LAL-D

FDA grants priority review to Intercept's NDA for obeticholic acid for primary biliary cirrhosis

Probuphine NDA resubmitted to FDA

First oral agent for Gaucher's disease launched in Japan

Initial results reported from phase I trial of RNAi therapeutic ALN-PCSsc

Dabrafenib-trametinib combination approved in the E.U. for BRAF V600 mutation-positive melanoma

Bristol-Myers Squibb gains exclusive right to acquire Promedior

Valeant licenses rights to brodalumab from AstraZeneca

European approval of Strensiq for pediatric-onset hypophosphatasia

Lipocine files U.S. NDA for testosterone replacement therapy LPCN-1021

Asahi Kasei announces launch date for Xiaflex in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...